152 related articles for article (PubMed ID: 11606406)
21. Cyclin D1 is a candidate oncogene in cutaneous melanoma.
Sauter ER; Yeo UC; von Stemm A; Zhu W; Litwin S; Tichansky DS; Pistritto G; Nesbit M; Pinkel D; Herlyn M; Bastian BC
Cancer Res; 2002 Jun; 62(11):3200-6. PubMed ID: 12036934
[TBL] [Abstract][Full Text] [Related]
22. Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma.
Giehl KA; Nägele U; Volkenandt M; Berking C
J Cutan Pathol; 2007 Jan; 34(1):7-14. PubMed ID: 17214848
[TBL] [Abstract][Full Text] [Related]
23. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
24. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
[TBL] [Abstract][Full Text] [Related]
25. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
26. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
27. Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma.
Collins KA; White WL
Am J Dermatopathol; 1995 Oct; 17(5):429-38. PubMed ID: 8599446
[TBL] [Abstract][Full Text] [Related]
28. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
29. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
30. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.
Cerroni L; Soyer HP; Kerl H
Am J Dermatopathol; 1995 Feb; 17(1):7-11. PubMed ID: 7695015
[TBL] [Abstract][Full Text] [Related]
31. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
32. Expression of the ets-1 proto-oncogene in melanocytic lesions.
Keehn CA; Smoller BR; Morgan MB
Mod Pathol; 2003 Aug; 16(8):772-7. PubMed ID: 12920221
[TBL] [Abstract][Full Text] [Related]
33. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
34. No evidence for c-erbB-2 overexpression in cutaneous melanoma.
Fink-Puches R; Pilarski P; Schmidbauer U; Kerl H; Soyer HP
Anticancer Res; 2001; 21(4A):2793-5. PubMed ID: 11724356
[TBL] [Abstract][Full Text] [Related]
35. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.
Persons DL; Arber DA; Sosman JA; Borelli KA; Slovak ML
Anticancer Res; 2000; 20(3B):1965-8. PubMed ID: 10928135
[TBL] [Abstract][Full Text] [Related]
36. Gene expression patterns in melanocytic cells: candidate markers for early stage and malignant transformation.
Meije CB; Hakvoort TB; Swart GW; Westerhof W; Lamers WH; Das PK
J Pathol; 2002 Jan; 196(1):51-8. PubMed ID: 11748642
[TBL] [Abstract][Full Text] [Related]
37. Micro-anatomy related antigen expression in melanocytic lesions.
Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
[TBL] [Abstract][Full Text] [Related]
38. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
[TBL] [Abstract][Full Text] [Related]
40. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]